Ivac-Xs15-cll01: Personalized Multi-Peptide Vaccination in Combination with the TLR1/2 Ligand XS15 in CLL Patients Undergoing BTK-inhibitor-based Regimens
Frontiers in Oncology（2024）
关键词
chronic lymphocytic leukemia,peptide vaccine,BTK-inhibitor,minimal residual disease,immunotherapy,phase I trial,personalized medicine
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要